Literature DB >> 18692485

Dexamethasone down-regulates ABCG2 expression levels in breast cancer cells.

Mylène Honorat1, Aurélia Mesnier, Attilio Di Pietro, Valérie Lin, Pascale Cohen, Charles Dumontet, Léa Payen.   

Abstract

The breast cancer resistance protein ABCG2 effluxes a variety of drugs and is believed to play an important role in multidrug resistance to chemotherapy. We show here for the first time that dexamethasone (DEX) and progesterone (PROG) are able to strongly inhibit ABCG2 expression in progesterone receptor (PR)-positive MCF7 and PR-negative MDA-MB-231 breast cells. In contrast, in the latter cells stably-transfected with progesterone receptor isoforms A and B, ABCG2 expression was strongly up-regulated by DEX and PROG. In addition, two other ligands of Pregnane X Receptor (PXR) and/or Glucocorticoid Receptor (GR) were also able to down-regulate ABCG2 expression in PXR- and GR-positive MCF7 cells. ABCG2 expression regulation by DEX likely resulted from the activation of PR-, PXR-, and/or GR-signaling pathways. ABCG2 expression inhibition by DEX was associated with increased sensitivity to mitoxantrone, a known ABCG2 substrate. The findings suggest that DEX may be useful in improving drug efficacy under certain conditions.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18692485     DOI: 10.1016/j.bbrc.2008.07.149

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  14 in total

1.  The Expression Level of S100A4 Protein Affects the Migration Activity of Breast Cancer Cells.

Authors:  E A Dukhanina; T N Portseva; A P Kotnova; E V Pankratova; S G Georgieva
Journal:  Dokl Biochem Biophys       Date:  2019-06-14       Impact factor: 0.788

Review 2.  Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistance.

Authors:  Karthika Natarajan; Yi Xie; Maria R Baer; Douglas D Ross
Journal:  Biochem Pharmacol       Date:  2012-01-11       Impact factor: 5.858

Review 3.  Role of the breast cancer resistance protein (BCRP/ABCG2) in drug transport--an update.

Authors:  Qingcheng Mao; Jashvant D Unadkat
Journal:  AAPS J       Date:  2014-09-19       Impact factor: 4.009

Review 4.  ATP-binding cassette efflux transporters in human placenta.

Authors:  Zhanglin Ni; Qingcheng Mao
Journal:  Curr Pharm Biotechnol       Date:  2011-04       Impact factor: 2.837

5.  MicroRNA expression is differentially altered by xenobiotic drugs in different human cell lines.

Authors:  Alice C Rodrigues; Xin Li; Laura Radecki; Yu-Zhuo Pan; Jerrold C Winter; Min Huang; Ai-Ming Yu
Journal:  Biopharm Drug Dispos       Date:  2011-07-28       Impact factor: 1.627

6.  ABCG2 regulatory single-nucleotide polymorphisms alter in vivo enhancer activity and expression.

Authors:  Rachel J Eclov; Mee J Kim; Aparna Chhibber; Robin P Smith; Nadav Ahituv; Deanna L Kroetz
Journal:  Pharmacogenet Genomics       Date:  2017-12       Impact factor: 2.089

7.  Breast cancer-resistance protein (BCRP1) in the fetal mouse brain: development and glucocorticoid regulation.

Authors:  Sophie Petropoulos; William Gibb; Stephen G Matthews
Journal:  Biol Reprod       Date:  2010-12-15       Impact factor: 4.285

8.  Time-dependent pharmacokinetics of dexamethasone and its efficacy in human breast cancer xenograft mice: a semi-mechanism-based pharmacokinetic/pharmacodynamic model.

Authors:  Jian Li; Rong Chen; Qing-Yu Yao; Sheng-Jun Liu; Xiu-Yun Tian; Chun-Yi Hao; Wei Lu; Tian-Yan Zhou
Journal:  Acta Pharmacol Sin       Date:  2017-11-09       Impact factor: 6.150

9.  MicroRNA-328 negatively regulates the expression of breast cancer resistance protein (BCRP/ABCG2) in human cancer cells.

Authors:  Yu-Zhuo Pan; Marilyn E Morris; Ai-Ming Yu
Journal:  Mol Pharmacol       Date:  2009-03-06       Impact factor: 4.436

10.  Glucocorticoid Receptor-Targeted Liposomal Codelivery of Lipophilic Drug and Anti-Hsp90 Gene: Strategy to Induce Drug-Sensitivity, EMT-Reversal, and Reduced Malignancy in Aggressive Tumors.

Authors:  Sujan Kumar Mondal; Sudhakar Jinka; Krishnendu Pal; Swetha Nelli; Shamit Kumar Dutta; Enfeng Wang; Ajaz Ahmad; Khalid M AlKharfy; Debabrata Mukhopadhyay; Rajkumar Banerjee
Journal:  Mol Pharm       Date:  2016-06-01       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.